

## CLAIMS

28. (Previously presented) A medicament, comprising:  
a plurality of coated drug particles, each of said coated drug particles having an average particle size of less than 50  $\mu\text{m}$  in diameter, the surface of said particles comprising at least a first coating layer of biodegradable and bio-compatible material, said coating layer being a continuous and non-porous layer, wherein an average thickness of said coating layer is between 1 and 500 nm.
29. (Previously presented) The medicament of claim 28, wherein said coating layer is exclusive of said drug provided by said drug particles.
30. (Original) The medicament according to claim 28, wherein said coating layer material is at least one selected from the group consisting of PLA, PGA, PLGA and cellulose compounds.
31. (Previously presented) The medicament according to claim 28, wherein said plurality of said coated drug particles have an average particle size of less than 20  $\mu\text{m}$  in diameter.
32. (Original) The medicament according to claim 28, wherein said coated drug particles have an average particle size of less than 10  $\mu\text{m}$  in diameter.

33. (Original) The medicament according to claim 28, wherein said coated drug particles have an average particle size of less than 1  $\mu\text{m}$  in diameter.
34. (Original) The medicament according to claim 28, wherein said coated drug particles have an average particle size of less than 0.1  $\mu\text{m}$ .
35. (Original) The medicament according to claim 28, wherein the average thickness of said coating layer is between 1 and 400 nm.
36. (Original) The medicament according to claim 28, wherein the average thickness of said coating layer is between 3 and 200 nm.
37. (Original) The medicament according to claim 28, wherein the average thickness of said coating layer is between 5 and 50 nm.
38. (Original) The medicament according to claim 28, wherein the average thickness of said coating layer is between 50 and 500 nm.
39. (Original) The medicament according to claim 28, wherein the average thickness of said coating layer is between 150 and 500 nm.
40. (Original) The medicament according to claim 28, wherein the average thickness of said coating layer is between 300 and 500 nm.

41. (Original) The medicament according to claim 28, wherein the average size of said coated drug particles is less than 50 nm in diameter.

42. (Original) The medicament according to claim 28, wherein the average size of said coated drug particles is less than 30 nm in diameter.

43. (Original) The medicament according to claim 28, wherein the average size of said coated drug particles is less than 10 nm in diameter.

44. (Original) The medicament according to claim 28, wherein the average size of said coated drug particles is less than 5 nm in diameter.

45-47. (Cancelled)

48. (Original) The medicament according to claim 28, wherein said coated drug particles comprise at least one drug selected from the group consisting of anti-allergics, antibiotics, anti-inflammatories and bronchodilatory drugs.

49. (Original) The medicament according to claim 28, wherein said coated drug particles comprise at least one drug selected from the group consisting of budesonide, triamcinolone acetonide and rifampicin.

50. (Previously presented) A pharmaceutical formulation comprising the medicament of claim 28 and a pharmaceutically acceptable solution.

51. (Original) The formulation according to claim 50, wherein said formulation has from 0.01% to 10 % by weight of said medicament relative to the total weight of said formulation.

52. (Original) The formulation according to claim 50 containing from 0.1 % to 1 % by weight of said medicament relative to the total weight of said formulation.

53. (Original) The formulation according to claim 50, wherein about 20 % to about 50 % by weight of said medicament is a respirable fraction.

54. (Original) The formulation according to claim 50, wherein at least 50 % by weight of said medicament is a respirable fraction.

55. (Original) The formulation according to claim 50, further comprising at least a second medicament.

56. (Original) The formulation according to claim 55, wherein said second medicament is a particulate medicament.

57. (Original) The formulation according to claim 55, wherein said second medicament comprises a medicament in accordance with claim 28.

58. (Original) The formulation according to claim 50, further comprising a first bronchodilatory medicament and a second medicament, said medicaments each being at least one selected from the group consisting of anti-inflammatory agents, bronchodilatory agents, antibiotic agents and anti-allergic agents.

59. (Original) The formulation according to claim 50, further comprising structure for aerosol administration of said formulation.

60. (Original) The formulation according to claim 59, wherein said structure for aerosol administration includes a propellant.

61. (Original) The formulation according to claim 60, wherein said propellant is at least one selected from the group consisting of fluorocarbons and hydrogen-containing chlorofluorocarbons.

62. (Original) A therapeutic kit comprising the medicament of claim 28 and instructions for the administration of said medicament.

63. (Original) A therapeutic kit comprising the formulation according to claim 50 and instructions for the administration of said medicament.

64. (Original) The therapeutic kit of claim 62, further comprising an aerosol delivery apparatus or a medical device suitable for pulmonary administration of said medicament.

65. (Original) The therapeutic kit of claim 63, further comprising an aerosol delivery apparatus or a medical device suitable for pulmonary administration of said medicament.

66. (Previously presented) A method for treating patients, comprising the steps of:

providing a medicament comprising a plurality of coated drug particles, each of said coated drug particles having an average particle size of less than 50  $\mu\text{m}$  in diameter, the surface of said particles comprising at least a first coating layer of biodegradable and bio-compatible material, said coating layer being a continuous and non-porous layer, wherein an average thickness of said coating layer is between 1 and 500 nm, and

treating a respiratory disorder or pulmonary infection in a human patient using said medicament.

67. (Previously presented) The method of claim 66, wherein said coated drug particles have an average particle size of less than 20  $\mu\text{m}$  in diameter.

68-70 (Cancelled)